Xenon Pharmaceuticals（XENE）株式概要
神経科学に特化したバイオ医薬品企業であるゼノン・ファーマシューティカルズ・インクは、神経疾患や精神疾患の患者を治療するための治療薬の発見、開発、提供に取り組んでいる。 詳細
XENE Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xenon Pharmaceuticals Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$60.77 |
| 52週高値 | US$72.66 |
| 52週安値 | US$35.60 |
| ベータ | 0.63 |
| 1ヶ月の変化 | -8.17% |
| 3ヶ月変化 | 12.18% |
| 1年変化 | 56.46% |
| 3年間の変化 | 59.71% |
| 5年間の変化 | 250.06% |
| IPOからの変化 | 478.76% |
最新ニュース
Seeking Alpha • Aug 11
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Summary Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027. Robust $1.2B cash position funds operations into 2029, supporting multiple late-stage programs and pipeline expansion. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 09
XENE: Upcoming NDA Filing And Kv7 Data Readouts Will Shape Risk Balance
Analysts lifted their fair value estimate for Xenon Pharmaceuticals to $69 from $63, citing updated models that reflect recent Street research and revised long term assumptions on revenue potential, margins, and future P/E expectations. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights both interest in the epilepsy opportunity and a set of clear caution flags that investors should factor into expectations for execution and valuation risk.
ナラティブ更新 • Jul 10
XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival
Analysts have lifted their fair value estimate for Xenon Pharmaceuticals from about $55.40 to about $80.56, reflecting updated models that incorporate revised assumptions for long term revenue potential, profit margins, and future P/E multiples in light of recent Street research and competitive positioning versus Biohaven. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights a mix of optimism on the epilepsy opportunity and caution around execution and competitive risk, particularly in comparison with Biohaven.ナラティブ更新 • Jun 26
XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter
The updated analyst price target for Xenon Pharmaceuticals has moved from $58.58 to $63.00, as analysts factor in refreshed models and recent Street research that includes higher targets from firms such as JPMorgan and Wells Fargo, alongside a modest trim from Needham. Analyst Commentary Recent Street research on Xenon Pharmaceuticals shows a mixed tone, with some large firms, including JPMorgan, lifting price targets while other bearish analysts trim expectations.Recent updates
Seeking Alpha • Aug 11
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Summary Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027. Robust $1.2B cash position funds operations into 2029, supporting multiple late-stage programs and pipeline expansion. Read the full article on Seeking Alphaナラティブ更新 • Aug 09
XENE: Upcoming NDA Filing And Kv7 Data Readouts Will Shape Risk Balance
Analysts lifted their fair value estimate for Xenon Pharmaceuticals to $69 from $63, citing updated models that reflect recent Street research and revised long term assumptions on revenue potential, margins, and future P/E expectations. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights both interest in the epilepsy opportunity and a set of clear caution flags that investors should factor into expectations for execution and valuation risk.ナラティブ更新 • Jul 10
XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival
Analysts have lifted their fair value estimate for Xenon Pharmaceuticals from about $55.40 to about $80.56, reflecting updated models that incorporate revised assumptions for long term revenue potential, profit margins, and future P/E multiples in light of recent Street research and competitive positioning versus Biohaven. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights a mix of optimism on the epilepsy opportunity and caution around execution and competitive risk, particularly in comparison with Biohaven.ナラティブ更新 • Jun 26
XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter
The updated analyst price target for Xenon Pharmaceuticals has moved from $58.58 to $63.00, as analysts factor in refreshed models and recent Street research that includes higher targets from firms such as JPMorgan and Wells Fargo, alongside a modest trim from Needham. Analyst Commentary Recent Street research on Xenon Pharmaceuticals shows a mixed tone, with some large firms, including JPMorgan, lifting price targets while other bearish analysts trim expectations.新しいナラティブ • Mar 27
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel based therapies for epilepsy, depression, bipolar disorder and pain. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 09
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?分析記事 • Oct 01
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Apr 18
Xenon- A Later Stage Story
Summary Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications. Despite broader biotech market challenges, Xenon's strong efficacy and safety data position it well, with significant interest from major pharma in neurology and neuropsychiatry. Read the full article on Seeking AlphaSeeking Alpha • Jan 16
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Summary Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time. I also believe its late-stage IP is diversified with ion channel modulators for pain and other neurological conditions. So it’s not overly exposed to Azetukalner. I concede that XENE has a premium valuation, but I think 2025 will provide significant clinical data that could justify a “Buy” rating at these levels. Read the full article on Seeking AlphaSeeking Alpha • Aug 09
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Summary Xenon Pharmaceuticals is a Canadian biopharma company targeting neurological diseases with a focus on ion channel-blocking technology. The clinical stage asset, azetukalner, is in late stage development for epilepsy and Major Depressive Disorder, showing promising results in reducing seizure frequency. Despite a history of failures and low trading volume, Xenon has a strong cash position and upcoming catalysts in phase 3 trials for their lead asset. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Summary Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. The company has experienced "setbacks" in recent trials, but its primary drug candidate, XEN1101, shows significant potential for treating epilepsy. Xenon has initiated Phase 3 clinical trials for XEN1101 and has received myriad positive ratings from analysts, but the stock may be vulnerable to profit-taking. An analysis around Xenon Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 19
Xenon started at outperform at Raymond James on experimental epilepsy drug
Raymond James has initiated Xenon Pharmaceuticals (NASDAQ:XENE) with an outperform rating citing the blockbuster potential of XEN1101, currently in phase 2 for epilepsy. The firm has a $52 price target (~46% upside based on Tuesday's close). Analyst Danielle Brill is confident that XEN1101 will be successful given its strong phase 2 results. She predicted a greater than $1B peak sales opportunity. Xenon (XENE) plans to initiate two identical phase 3 clinical trials. She noted that the the candidate, which is also under development for major depressive disorder, could further benefit from proof-of-concept data in that indication expected in 2023. Brill added that the company's pipeline also presents growth opportunities with XEN496 in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE), and NBI-921352 for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). XEN1101 is also under investigation for primary generic clonic tonic seizures (PGTCS). In August, BofA started Xenon (XENE) with a buy rating also citing the blockbuster potential of XEN1101 for epilepsy.Seeking Alpha • Sep 06
Putting Xenon Pharmaceuticals Back In The Spotlight
Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "Potential has a shelf life." - Margaret Atwood We last looked in on Xenon Pharmaceuticals (XENE) nearly nine months ago. In the summary of that article, the conclusion was that the company had some promising attributes and was worthy of a small 'watch item' via covered call positions. That turned out to be a profitable trade. Time for another potential round trip? We update the investment thesis on Xenon below. Seeking Alpha Company Overview: Xenon Pharmaceuticals is a clinical-stage biotech company focused on developing therapeutics to treat patients with neurological disorders. The company is based just outside of Vancouver, Canada. The stock trades just under $40.00 a share and sports an approximate market cap just north of $2.4 billion. August Company Presentation The company has several compounds in development as can be seen by the pipeline chart above. August Company Presentation The most important asset in development is a candidate called for the moment XEN1011. This is a next generation Kv7 potassium channel opener with potential applications in treating the focal onset seizures which occurs in epileptics as well as other potential neurological disorders. August Company Presentation A Phase 2b trial produced encouraging results in the fourth quarter of last year. The company then disclosed new, compelling efficacy data from that study 'X-TOLE' in June of this year. A Phase 2 study 'X-TOLE2' should initiate by the end of this year, followed shortly by a Phase 3 trial X-TOLE3. If successful, the company plans to submit a market application around this compound to treat epilepsy. August Company Presentation The compound is also in development for other neurological disorders. The company currently has a Phase 2 'X-NOVA' study underway examining XEN1101 in major depressive disorder or MDD. This trial in parallel with an investigator-led Phase 2 MDD study led by Xenon's collaborators at Mount Sinai. Topline results should be out in 2023. August Company Presentation XEN1101 is also now targeting primary generalized tonic clonic seizures or PGTCS. Management plans to initiate a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in PGTCS. This study should kick soon after initiation of the X-TOLE2 trial. August Company Presentation Another compound 'XEN496' is being developed to treat rare KCNQ2-DEE pediatric epilepsy. A Phase 3 study called EPIK, is ongoing to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. This trial should complete sometime in 2023. August Company Presentation Finally the company has licensed a selective Nav1.6 sodium channel inhibitor 'XEN901', now known as NBI-921352, to Neurocrine Biosciences (NBIX). That compound is in Phase 2 development for a couple of indications. As the result of this licensing agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties on any eventual commercialization. Analyst Commentary & Balance Sheet: Since second quarter results were posted on August 9th, five analyst firms including Needham and Wedbush have reissued Buy ratings on XENE. Price targets proffered ranged from $46 to $52 a share. On August 29th, Bank of America initiated the shares as a new Buy with a $45 a share price target. Here is the commentary from the bank's analyst at the time of that call.Seeking Alpha • Aug 29
Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Bank of America launched its coverage on clinical-stage biotech Xenon Pharmaceuticals Inc. (NASDAQ:XENE) with a Buy rating on Monday, arguing that the company’s mid-stage epilepsy candidate XEN1101 is poised to become a blockbuster drug. XEN1101 belongs to a class of drugs known as Kv7 potassium channel openers, and the drug is expected to undergo its Phase 3 program in H2 2022, XENE said this month. The analysts led by Jason M. Gerberry point to the blockbuster potential of XEN1101 ahead of important catalysts for its safety data, second confirmatory, and label expansion studies. The ease of use, novel mechanism of action, and strong efficacy differentiate XEN1101 from other anti-seizure medications, the team with a $48 per share target on XENE argued. Wall Street stands firmly behind the prospects of Xenon (XENE) with eleven Buy ratings and no Hold or Sell ratings.Seeking Alpha • Dec 13
Sizing Up Xenon Pharmaceuticals
Today, we look at Xenon Pharmaceuticals, a clinical-stage biotech concern with several products advancing in its pipeline. The stock recently has surged on top of positive mid-stage trial results. The shares have also seen some insider buying lately as well. A full investment analysis follows in the paragraphs below.株主還元
| XENE | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -2.5% | 6.9% | -1.5% |
| 1Y | 56.5% | 45.3% | 17.9% |
業界別リターン: XENE過去 1 年間で45.3 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: XENE過去 1 年間で17.9 % の収益を上げたUS市場を上回りました。
価格変動
| XENE volatility | |
|---|---|
| XENE Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: XENE 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: XENEの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 364 | Ian Mortimer | www.xenon-pharma.com |
神経科学に特化したバイオ医薬品企業であるゼノン・ファーマシューティカルズ・インクは、神経疾患や精神疾患の患者を治療するための治療薬の発見、開発、提供に取り組んでいる。同社の製品候補には、焦点発作や一次性全般性強直間代発作などのてんかんや、大うつ病性障害や双極性うつ病などの精神神経疾患の治療薬として第3相臨床開発段階にある、新規の強力なKv7カリウムチャネル開口薬であるアゼツカルナーなどがある。さらに、フェーズ1の単回/複数回投与の製品には、疼痛治療薬としてナトリウムチャネルを標的とするXEN1701とKv7カリウムチャネルを標的とするXEN1120がある。同社はNeurocrine Biosciences, Inc.と、Nav1.2/1.6ナトリウムチャネル阻害剤NBI-921355の開発に関するライセンスおよび共同研究契約を結んでおり、特定のてんかんの治療薬として臨床第1相試験を実施中。ゼノン・ファーマシューティカルズ・インクは1996年に設立され、カナダのバーナビーに本社を置いている。
Xenon Pharmaceuticals Inc. 基礎のまとめ
| XENE 基礎統計学 | |
|---|---|
| 時価総額 | US$5.78b |
| 収益（TTM） | -US$409.19m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-14.4x
PER（株価収益率XENE は割高か？
公正価値と評価分析を参照収益と収入
| XENE 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$352.49m |
| 売上総利益 | -US$352.48m |
| その他の費用 | US$56.71m |
| 収益 | -US$409.19m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -4.23 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
XENE の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/21 14:37 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Xenon Pharmaceuticals Inc. 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |